Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer. METHODS: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association Consortium (BCAC). RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR) ¼ 0.97, 95% confidence interval (CI) 0.95 -0.99, P ¼ 4.6 Â 10 À3 ), but did not reach significance in the BCAC replication study alone (OR ¼ 0.98, 95% CI 0.96 -1.01, P ¼ 0.139). CONCLUSION: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer British Journal of Cancer (2011 Cancer ( ) 105, 1934 Cancer ( -1939 Cancer ( . doi:10.1038 Cancer ( /bjc.2011 Published online 27 October 2011 & 2011 Cancer Research UK Keywords: genetic susceptibility; neoplasms; association study Phosphatidylinositol-3 kinases (PI3Ks) constitute a lipid kinase family integral to signalling pathways that regulate many cancerrelated processes, including cell proliferation, adhesion, apoptosis, survival and motility (Fruman et al, 1998; Cantley, 2002) . Alteration of PI3K family members, such as amplification of the phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) oncogene on chromosome 3q26 that encodes the p110a catalytic subunit of PI3K, are commonly observed in human cancers. Amplification and overexpression of PIK3CA results in increased production of the phosphatidylinositol-3,4,5-triphosphate second messenger, hyperactivation of the PI3K/AKT pathway, and stimulation of cellular transformation and tumour progression (Shayesteh et al, 1999; Ma et al, 2000; Fresno Vara et al, 2004; Saal et al, 2005; Samuels and Ericson, 2006) . Somatic mutations in PIK3CA are also common in colon (18 -32%), gastric (4 -25%), endometrial (36%), liver (36%), brain (27%) and breast (18 -40%) tumours (Bachman et al, 2004; Campbell et al, 2004; Samuels et al, 2004; Karakas et al, 2006; Ligresti et al, 2009) . Functional analyses have shown that many of these mutations activate PIK3CA enzymatic activity and stimulate downstream AKT signalling, promoting growth factor-independent growth and metastasis Samuels and Ericson, 2006) .
In breast tumours, PIK3CA mutations have been consistently associated with ER-positive and human epidermal growth factor receptor-2 (HER2)-positive tumour status (Saal et al, 2005; Li et al, 2006; Perez-Tenorio et al, 2007; Stemke-Hale et al, 2008 ) (Saal et al, 2005; Perez-Tenorio et al, 2007) . The correlation between these mutations and breast cancer prognosis is less clear, with several studies reporting associations between PIK3CA mutations and lymph node metastasis and worse overall and breast cancer-specific survival (Saal et al, 2005; Li et al, 2006; Lai et al, 2008; Aleskandarany et al, 2010) , whereas other studies have reported associations with longer survival particularly among patients with ER-positive, HER2-negative tumours (Perez-Tenorio et al, 2007; Kalinsky et al, 2009; Loi et al, 2010) .
Although the pathological and clinical significance of PIK3CA somatic mutations has been well studied, the contribution of inherited variation in this important oncogene to risk of breast cancer is unknown. Here we investigated the influence of germline variation in PIK3CA on breast cancer risk.
MATERIALS AND METHODS

Mayo clinic breast cancer study
The details of the Mayo Clinic Breast Cancer case -control Study (MCBCS) have been described previously (Wang et al, 2008) . Briefly, cases were comprised of Caucasian women with invasive breast cancer diagnosed within 6 months of ascertainment with no prior history of cancer. Controls were comprised of Caucasian women visiting the Mayo Clinic for general medical exams in the Department of Internal Medicine with no prior history of cancer. Participants were recruited under an Institutional Review Board approved protocol. A total of 798 cases and 843 controls were utilised for stage 1 genotyping (Table 1) .
Replication studies
The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer case -control study and 26 case -control studies from Breast Cancer Association Consortium (BCAC) contributed data to these analyses (described in Supplementary 
Genotyping
Four haplotype-tagging single-nucleotide polymorphisms (SNPs) within PIK3CA (rs13320527, rs3729692, rs1607237, rs9838117) were selected (r 2 40.80 in European -American genotype data from HapMap release 21). A total of 1741 Mayo Clinic samples (798 cases, 843 controls and 100 duplicates) were genotyped on custom oligo pool assays at Illumina Corporation (San Diego, CA, USA) using the Illumina GoldenGate assay. All SNPs had genotype call rates 495%. Concordance between duplicate samples was 100%. Genotyping of rs1607237 in CGEMS and BCAC was performed using a TaqMan allelic discrimination assay or the Sequenom platform (Sequenom, San Diego, CA, USA) via standard protocols. Genotyping concordance was verified with internal duplicates and overall data quality was ensured using independent genotyping of 96 CEU samples by each genotyping center (Garcia-Closas et al, 2008) . All studies met the specified criteria for call rate (495%).
Pathology and tumour markers
The collection of pathology and tumour marker information for BCAC has been described previously (Yang et al, 2011) . Pathology data were also available for 900 CGEMS subjects. Briefly, studies provided information on histopathological subtype, grade of differentiation, tumour size, nodal involvement and stage at diagnosis of breast tumours. All studies except BBCS, GC-HBOC and HMBCS provided data on ER and progesterone receptor (PR) status of tumours, and 12 studies provided data on HER2 (Supplementary Table 2 ). ER/PR status was most commonly defined using data from medical records. Oestrogen receptor and PR negative status was defined as o10% of the tumour cells stained. Human epidermal growth factor receptor-2-negative status was typically defined as a score of 0 or 1 þ on a HER2 immunohistochemistry (IHC) scale of 0 -3 þ .
Statistical methods
Evidence of departure from Hardy -Weinberg equilibrium (HWE) was assessed in controls using a goodness of fit test and none was observed (HWE PX0.001). Single-nucleotide polymorphism associations were tested using unconditional logistic regression adjusting for age and state of residence in a log-additive model. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) separately for heterozygotes and rare homozygotes. The association between rs1607237 and breast cancer risk in stage 1 of the CGEMS GWAS was evaluated as previously described (Thomas et al, 2009) . Associations with breast cancer risk in the BCAC studies and the combined BCAC, MCBCS and CGEMS studies were evaluated using unconditional logistic regression adjusting for study center. A likelihood ratio test of heterogeneity by age groups was not significant (P ¼ 0.10), and further adjustment for age did not change the results. Analyses of pathology-specific subsets of cases were conducted using polytomous regression with controls as the reference outcome, adjusting for study site. Table 2 ). However, when combining all genotype data from the three stages of this study (MCBCS, CGEMS and BCAC; Supplementary Table 3), rs1607237 was significantly associated with risk of breast cancer (OR ¼ 0.97, 95% CI 0.95 -0.99, P ¼ 9.5 Â 10 À3 ). Similarly, a significant association was observed when considering only women of European ancestry in the combined analysis (OR ¼ 0.97, 95% CI 0.95 -0.99, P ¼ 4.6 Â 10 À3 ; (Table 2) . There was no evidence of heterogeneity by study site among the 25 Caucasian studies (P ¼ 0.14; Supplementary Figure 2) .
To further understand the association with breast cancer, we restricted the analysis to women with invasive breast cancer. Rs1607237 was associated with a reduced risk of invasive breast cancer (OR ¼ 0.97, 95% CI 0.95 -0.99, P ¼ 0.012; Table 2), whereas no association with risk of ductal carcinoma in situ was observed (OR ¼ 0.93, 95% CI 0.85 -1.02, P ¼ 0.12). In addition, we explored differences in PIK3CA SNP associations in the combined data set by tumour subtype (Supplementary Table 4 ). The rs1607237 variant was not associated with any subtypes defined by ER, PR or HER2 status, although it is important to note the reduction in sample size when restricting to these tumour subtypes.
DISCUSSION
Here we report an association between inherited variation in the oncogene PIK3CA and risk of breast cancer in a large, three-stage analysis utilising nearly 75 000 subjects from 27 case -control study studies. We show that rs1607237 is significantly associated with a small decrease in breast cancer risk (OR ¼ 0.97, 95% CI 0.95 -0.99, P ¼ 9.5 Â 10 À3 ) in all studies combined and when considering only women of European ancestry in the combined studies (OR ¼ 0.97, 95% CI 0.95 -0.99, P ¼ 4.6 Â 10 À3 ). However, the association did not achieve significance in the large third stage involving only BCAC studies. Although the first two stages of our analysis suggest an association between PIK3CA and breast cancer risk, our inability to confirm this finding in the BCAC studies suggests that the result should be interpreted with caution.
We further explored the linkage disequilibrium patterns in the PIK3CA coding and promoter regions to better understand the relationship between rs1607237 and other variation in this region. Rs1607237 was not in strong linkage disequilibrium with two nonsynonymous polymorphic variants in the coding region of PIK3CA, rs1051399 (r 2 ¼ 0.0060) and rs3729680 (r 2 ¼ 0.034), which had been genotyped in HapMap samples of European ancestry. However, an additional 18 non-synonymous variants were either not polymorphic or had not been genotyped in the HapMap samples, making inference about the relationship between rs1607237 and all variants of unknown significance in the PIK3CA coding region difficult. In addition, two PIK3CA promoter SNPs were in low LD with rs1607237 (rs9831234, r 2 ¼ 0.16; rs2865084, r 2 ¼ 0.038). However, it remains possible that PIK3CA promoter SNPs that were not captured in this study are related to breast cancer risk. It is also important to note that the effect estimate for rs1607237 in the BCAC replication studies and in the overall BCAC, MCBCS and CGEMS studies is quite small (OR ¼ 0.97). This limits our statistical power to detect significant associations in these studies despite the large sample size, particularly in analyses utilising pathology information that is available for only a subset of subjects. Similarly, we had limited power to detect associations in the original MCBCS study with the three non-significant PIK3CA SNPs. Thus, it remains possible that evaluation of these variants in the larger BCAC cohort might detect associations with risk. While the effect of rs1607237 on risk is small, the association between inherited variation in this important oncogene and breast cancer risk does provide valuable biological insight into the development of this disease. Validation of rs1607237 in GWAS studies from other large collaborative groups and additional studies by BCAC with detailed pathology information are necessary to confirm this association. Functional evaluation of this variant is needed to fully understand the relationship between inherited PIK3CA variation and breast cancer risk. 
